CN1507442A - 激活人的过氧化物酶体增殖物激活受体的呋喃和噻吩衍生物 - Google Patents

激活人的过氧化物酶体增殖物激活受体的呋喃和噻吩衍生物 Download PDF

Info

Publication number
CN1507442A
CN1507442A CNA028096940A CN02809694A CN1507442A CN 1507442 A CN1507442 A CN 1507442A CN A028096940 A CNA028096940 A CN A028096940A CN 02809694 A CN02809694 A CN 02809694A CN 1507442 A CN1507442 A CN 1507442A
Authority
CN
China
Prior art keywords
methyl
phenyl
trifluoromethyl
acetate
furyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028096940A
Other languages
English (en)
Chinese (zh)
Inventor
P��J��˹���ά��
P·J·贝斯维克
F����ķ����
C·C·F·哈姆莱特
ض�
V·帕特尔
Л
M·L·谢拉
��������ķ������
N·G·拉姆斯登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1507442A publication Critical patent/CN1507442A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
CNA028096940A 2001-05-11 2002-05-09 激活人的过氧化物酶体增殖物激活受体的呋喃和噻吩衍生物 Pending CN1507442A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0111523.7 2001-05-11
GBGB0111523.7A GB0111523D0 (en) 2001-05-11 2001-05-11 Chemical compounds

Publications (1)

Publication Number Publication Date
CN1507442A true CN1507442A (zh) 2004-06-23

Family

ID=9914442

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028096940A Pending CN1507442A (zh) 2001-05-11 2002-05-09 激活人的过氧化物酶体增殖物激活受体的呋喃和噻吩衍生物

Country Status (20)

Country Link
US (1) US7091237B2 (enExample)
EP (1) EP1392674B1 (enExample)
JP (1) JP2004534035A (enExample)
KR (1) KR20040023600A (enExample)
CN (1) CN1507442A (enExample)
AT (1) ATE301649T1 (enExample)
BR (1) BR0209468A (enExample)
CA (1) CA2446797A1 (enExample)
CO (1) CO5540343A2 (enExample)
CZ (1) CZ20033064A3 (enExample)
DE (1) DE60205481T2 (enExample)
ES (1) ES2247322T3 (enExample)
GB (1) GB0111523D0 (enExample)
HU (1) HUP0304051A3 (enExample)
IL (1) IL158332A0 (enExample)
MX (1) MXPA03010285A (enExample)
NO (1) NO20034986D0 (enExample)
PL (1) PL367478A1 (enExample)
WO (1) WO2002092590A1 (enExample)
ZA (1) ZA200308352B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117500791A (zh) * 2021-03-08 2024-02-02 阿比奥尼克斯制药公司 可用于治疗肝脏疾病的化合物

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
WO2003016291A1 (en) 2001-08-10 2003-02-27 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
ITRM20020014A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
JP2005035966A (ja) * 2002-09-06 2005-02-10 Takeda Chem Ind Ltd フランまたはチオフェン誘導体およびその医薬用途
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7504433B2 (en) * 2003-01-06 2009-03-17 Eli Lilly And Company Thiophene derivative PPAR modulators
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1493739A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
RU2374230C2 (ru) 2003-11-05 2009-11-27 Ф.Хоффманн-Ля Рош Аг Фенильные производные в качестве ppar агонистов
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
GB0403148D0 (en) * 2004-02-12 2004-03-17 Smithkline Beecham Corp Chemical compounds
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
MX2007010511A (es) * 2005-02-28 2007-11-07 Nippon Chemiphar Co Activador para el receptor ( activador del proliferador peroxisoma.
US7982050B2 (en) 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
RU2007148439A (ru) * 2005-05-25 2009-06-27 Ниппон Кемифар Ко., Лтд. (JP) Активатор для рецептора, активируемого пролифератором пероксисом
BRPI0616465A2 (pt) 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
US20090012133A1 (en) * 2006-01-10 2009-01-08 Smithkline Beecham Corporation Polymorphic Form of -Acetic Acid
EP2014652B1 (en) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
JO2868B1 (en) * 2006-08-22 2015-03-15 رانبكسي لابوراتوريز ليمتد Inhibitors of metabolic protein protein enzyme
FR2910894A1 (fr) * 2006-12-29 2008-07-04 Genfit Sa Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation.
EP2114396A4 (en) 2006-12-29 2010-03-10 Salk Inst For Biological Studi METHOD FOR IMPROVING TRAINING PERFORMANCE
JP2010519308A (ja) * 2007-02-23 2010-06-03 イーライ リリー アンド カンパニー ペルオキシソーム増殖剤活性化受容体修飾因子
US20100063041A1 (en) * 2007-03-07 2010-03-11 Ho-Sang Moon Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
DE102008007400A1 (de) * 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
MX2010011252A (es) 2008-04-15 2010-11-30 Nippon Chemiphar Co Activador para el receptor activado por el proliferador de peroxisoma.
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
WO2014159054A1 (en) * 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
NZ710855A (en) * 2013-03-14 2020-03-27 Dow Agrosciences Llc Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117500791A (zh) * 2021-03-08 2024-02-02 阿比奥尼克斯制药公司 可用于治疗肝脏疾病的化合物

Also Published As

Publication number Publication date
US20040157890A1 (en) 2004-08-12
KR20040023600A (ko) 2004-03-18
JP2004534035A (ja) 2004-11-11
DE60205481T2 (de) 2006-05-24
BR0209468A (pt) 2004-08-03
HUP0304051A2 (hu) 2004-04-28
ES2247322T3 (es) 2006-03-01
ATE301649T1 (de) 2005-08-15
CA2446797A1 (en) 2002-11-21
CO5540343A2 (es) 2005-07-29
IL158332A0 (en) 2004-05-12
PL367478A1 (en) 2005-02-21
WO2002092590A1 (en) 2002-11-21
ZA200308352B (en) 2005-01-27
EP1392674B1 (en) 2005-08-10
CZ20033064A3 (cs) 2004-02-18
NO20034986L (no) 2003-11-10
GB0111523D0 (en) 2001-07-04
NO20034986D0 (no) 2003-11-10
US7091237B2 (en) 2006-08-15
EP1392674A1 (en) 2004-03-03
MXPA03010285A (es) 2004-03-09
DE60205481D1 (de) 2005-09-15
HUP0304051A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
CN1164579C (zh) 噻唑和噁唑衍生物以及它们的药物应用
CN1252057C (zh) 用于治疗与paar有关的疾病的噻唑衍生物
CN1578659A (zh) 过氧化物酶体增殖剂激活的受体(ppar)的调节剂
CN1543451A (zh) 过氧化物酶体增生剂激活的受体的调节剂
CN1674897A (zh) 作为hppar激活剂的苯基链烷酸和苯氧基链烷酸衍生物
JP4234431B2 (ja) ヒトペルオキシソーム増殖因子活性化受容体の活性化剤としてのチアゾール及びオキサゾール誘導体
CN1093124C (zh) 对PPAR－γ具有激动剂活性的取代的4－羟基－苯基alcanoic acid衍生物
CN1402716A (zh) 作为HPPARα激活剂的、取代的噁唑与噻唑衍生物
CN1129576C (zh) 用作环氧酶－2抑制剂的苯基杂环化合物
CN1066441C (zh) 异唑基苯基磺酰胺的衍生物及其在制备内皮缩血管肽拮抗药中的应用
CN1909902A (zh) 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物
CN1279026C (zh) 前列腺素内过氧化物h合酶生物合成抑制剂
CN1215059C (zh) 新的杂环化合物及其盐和它们的医药用途
CN100349856C (zh) 丙酸衍生物及其作为hPPAR活化剂的用途
CN1946666A (zh) 用于治疗代谢性疾病的化合物、药物组合物和方法
CN1503774A (zh) 羧酸衍生物及其盐
CN1308297C (zh) 氨基磺酸苯基酯衍生物
CN1509173A (zh) 用作糖尿病治疗中的PPAR－α和PPAR－γ激活剂的羧酸取代的噁唑衍生物
CN1649820A (zh) 调节ppar活性的化合物及其制备方法
CN1794989A (zh) 用于治疗糖尿病的n－(((((1,3－噻唑－2－基)氨基)羰基)苯基)磺酰基)苯丙氨酸衍生物及相关化合物
CN1529698A (zh) 用于治疗心血管及有关疾病的噻唑或噁唑衍生物
CN1767823A (zh) 哮喘和过敏性炎症调节剂
CN1751037A (zh) 作为ppar调节剂的磺酰胺衍生物
CN1226555A (zh) 抗真菌剂及其制备方法和中间体
CN1681763A (zh) 化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication